Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Publication Type:

Journal Article


Cancer, Volume 112, Issue 10, p.2181-7 (2008)


2008, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chemotherapy, Adjuvant, Cisplatin, Combined Modality Therapy, Cystectomy, Doxorubicin, Female, Fluorouracil, Humans, Male, methotrexate, Middle Aged, Muscle Neoplasms, Neoadjuvant Therapy, Prognosis, Public Health Sciences Division, Survival Rate, Treatment Outcome, Urinary Bladder Neoplasms, Vinblastine


Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients.